BC Platforms taking part in EU program for cancer therapies

BC Platforms (BCP), a global provider of data management and analysis services for the healthcare sector based in Zurich, has been designated as lead partner for the ONCOVALUE project of the European Union (EU). The European Commission, the politically independent executive arm of the EU, has entrusted Helsinki University Hospital (HUS) with leading the consortium project within the framework of its Horizon research program. The Zurich-based firm will play a vital role in the development of the technical architecture and data analysis, further details of which can be found in a press release issued by BCP.

ONCOVALUE is a system that functions on the basis of Artificial Intelligence (AI), which can analyze the efficacy of novel cancer therapies in real time. To achieve this, it standardizes data processing in hospitals, which lead to an improvement in the cost-effectiveness and sustainability of cancer care across Europe. To this end, the EU has provided a budget of 7 million euros for the project.

The aim here is to convert unstructured patient data from medical records and images into structured data and clinical evidence about the use and potential benefit of a medical device or drug. This is intended to support clinical professionals in treatment management and cooperation with health authorities.

Across the four years of the project, around 40,000 European patients from the consortium hospitals will take part in the study each year. In the view of Tero Silvola, CEO of BC Platforms, the fact that ONCOVALUE will open the door to widespread integration of real-world data “should lead to better, more environmentally sustainable therapies, technologies, and digital solutions for cancer care”.